| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 1/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Pharmaceutical Intermediate 99% Raw Material CAS 571190-30-2 Palbociclib Powder
| Product name:Ribociclib Powder |
| Other Name: LEE011,Ribociclib 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide |
| Appearance:White Powder |
| CAS:1211441-98-3 |
| M.F:C23H30N8O |
| M.W.:434.54 |
| Specification:99% |
Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer developed. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy by any organization, and as of December 2017 has been prescribed more than 90,000 times.
Related Product
| Product Name | CAS No. | Product Name | CAS No. |
| Lufenuron | 103055-07-8 | Toltrazuril | 69004-03-1 |
| Nitenpyram | 120738-89-8 | Praziquantel/Biltricide | 55268-74-1 |
| Fenbendazole | 43210-67-9 | Tetramisole Hcl | 5086-74-8 |
| Levamisole | 14769-73-4 | Ponazuril | 9004-4-2 |
| Diclazuril | 101831-37-2 | Florfenicol | 73231-34-2 |
| Ivermectin | 70288-86-7 | Enrofloxacin Hcl | 112732-17-9 |
| Albendazole | 54965-21-8 | Mebendazole | 31431-39-7 |
| ITEM | SPECIFICATION | RESULT | METHOD |
| Appearance | White powder, neutral odor, highly hygroscopic | Conforms | Visual |
| Identification | Standard solution and test solution same spot,RF | Conforms | TLC |
| Specific Optical | -2.4°~ -2.8° | -2.72° | |
| Heavy metals (as PB) | ≤10ppm | Conforms | AAS |
| Sulfate (SO4) | ≤0.02% | Conforms | Colorimetry |
| Chloride (Cl) | ≤0.02% | Conforms | Colorimetry |
| Phosphate Ion (P) | ≤5ppm | Conforms | Colorimetry |
| Residual solvent(ethanol) | ≤1.0% | Conforms | HS-GC |
| pH | 4.5~7.0 | 5.10 | |
| Related substance | Spot not bigger than standard solution spot | No spot | TLC |
| Water Content | ≤2% | 0.26% | KF |
| Assay (dried basis) | 98.0%--102.0% | 99.48% | Potentiometric titration |
| Assay (dried basis) | 98.5%--100% | 99.2% | HPLC |
Function:
Indicated for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women.
Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer developed. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy by any organization.
){kind=link}